DiscoverCNS[podcast] Effectiveness of new drug-resistant TB treatment is maintained with reduction in dosage and duration of Linezolid
[podcast] Effectiveness of new drug-resistant TB treatment is maintained with reduction in dosage and duration of Linezolid

[podcast] Effectiveness of new drug-resistant TB treatment is maintained with reduction in dosage and duration of Linezolid

Update: 2022-09-11
Share

Description

<iframe allowfullscreen="" frameborder="0" height="30" mozallowfullscreen="true" src="https://archive.org/embed/conor-podcast" webkitallowfullscreen="true" width="470"></iframe>
This podcast features Dr Conor Tweed, Honorary Clinical Lecturer, Medical Research Council (MRC) Clinical Trials Unit at University College London (UCL), who is in conversation with CNS founding Managing Editor and Executive Director Shobha Shukla. Jessica Wiggs, Senior Communication Specialist of TB Alliance (Global Alliance of TB Drug Development, www.TBalliance.org) joins the conversation. 

Listen to this podcast on Apple Podcasts, Amazon Music, Google Podcasts, Spotify, Stitcher, TuneIn, aCast, Podtail, BluBrry, Himalaya, ListenNotes, American Podcasts, CastBox FM, Ivy FM, Player FM, and other podcast streaming platforms.
Thanks

CNS team
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

[podcast] Effectiveness of new drug-resistant TB treatment is maintained with reduction in dosage and duration of Linezolid

[podcast] Effectiveness of new drug-resistant TB treatment is maintained with reduction in dosage and duration of Linezolid

CNS www.citizen-news.org